PepGen’s stock skyrockets on record-breaking DM1 trial data

PepGen's stock surged 132% after its Phase II trial for PGN-EDODM1 in myotonic dystrophy type 1 (DM1) met endpoints, showing high genetic modulation and functional improvements. The stock later closed at $4.61, up 92.9% from the previous close. The trial demonstrated significant splicing correction and tolerability, with data supporting continued development. PepGen expects more data in 2027.

Original reporting
Published Nov 11, 2026, 6:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 6:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
PepGen’s stock skyrockets on record-breaking DM1 trial data — source image
Decision brief

The 30-second read

Med
01

Why it matters

The data positions PepGen as a leading candidate in the DM1 therapeutic space, potentially attracting partnership interest and boosting its valuation.

02

Market read

First‑report of a breakthrough Phase II trial for a rare disease, driving a sharp stock rally and likely influencing the broader gene‑therapy sector.

03

What to watch

Small patient cohort (6 treated) and lack of long‑term safety data could temper enthusiasm.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

PepGen (Nasdaq: PGN) announced its FREEDOM2‑DM1 Phase II trial results, showing unprecedented splicing correction and functional gains in myotonic dystrophy type 1 patients.

Market effects

May boost sentiment for the rare‑disease gene‑therapy sector and other DM1‑focused biotech firms.

Primarily affects US‑listed biotech investors; limited broader market effect.

Highlights progress in antisense oligonucleotide therapies, relevant to global biotech R&D pipelines.

Counterpoint

Phase II success does not guarantee Phase III outcomes; investors may wait for larger trials before committing.

Key entities

  • PepGen

    Nasdaq‑listed biotech developing antisense oligonucleotide therapies.

  • Dr. Hanns Lochmüller

    Study investigator providing expert commentary on trial significance.

Related articles

$PEPGHighAI 8/10

PepGen Stock Doubles in One Session - Here's Why

PepGen Inc. (PEPG) stock surged 111.30% to $5.05 on Tuesday after reporting positive Phase 2 trial results for its myotonic dystrophy type 1 treatment, showing significant splicing correction and functional improvements in patients. The company reported a 46.5% average muscle splicing correction at 10 mg/kg dose, with notable gains in mobility and hand grip strength. PepGen expects to release further data in 2027.